Weight loss drugs for pets may have a place in very specific medical situations, but they should never replace thoughtful care, nutrition, and movement, nor should they become the next quick-fix trend for animals or humans.
A New Era: Diet Drugs for Cats
A biopharmaceutical company in San Francisco is now testing a GLP‑1 drug implant (MEOW‑1) for cats. Yes, that’s the real name. This is not satire. MEOW-1 is designed to release medication continuously for up to six months. The device uses exenatide, a GLP‑1 drug related to the same class as human medications like Ozempic and Mounjaro, and early company data suggest it may safely help cats lose weight and improve their metabolic health.
The trial plans to include up to 50 cats, with weight changes assessed at three and six months, and the company hopes to seek FDA approval around 2027–2028 if results are favorable. The projected cost to pet owners is about $100 USD per month, which raises immediate questions about access, equity, and if this is really the best way to invest in our pets’ health.
My Cat, Diabetes, and Hard Lessons
Long before GLP‑1 implants for cats were in the news, I had a cat with Type 2 Diabetes. If you’ve been following me for a while, you may be familiar with Meggie’s story. She became overweight because, while I worked late hours, she was overfed and under‑exercised. This led to her diabetes. I have also been told that older female calico cats have a higher incidence of this, too. So the perfect storm. Her story is a personal reminder that small daily choices around food and movement can have enormous consequences for our animals.
I immediately changed her diet and trained my helper to measure her food proportions rather than just fill her bowl when she meowed. I worked to get her moving more, and she gradually lost weight, though her older pancreas still needed insulin support. She went on to live to be 19 years old. Meggie and my son were close, and they also had diabetes in common – although different types. Meggie’s story is proof that if you struggle with weight gain, consistent care and lifestyle changes still matter profoundly.
What GLP‑1s Might Offer Pets
There is no doubt that weight is a genuine health problem for many domestic cats. Over half are now estimated to be overweight or obese. The company behind MEOW‑1 argues that medically supported weight loss can extend life, reduce diabetes risk, relieve osteoarthritis pain, and improve cardiovascular function and insulin sensitivity.
GLP‑1 medications work by helping the body release insulin more effectively and by slowing how fast food moves through the stomach, which reduces appetite and can lead to weight loss. In a strictly medical sense, this kind of tool could be life-changing for a small group of animals with severe obesity or metabolic disease, especially when other interventions have failed.
The Problem With Quick Fixes
Even if GLP‑1 implants prove safe and effective in cats, there is a real risk that they will be marketed or perceived as an easy shortcut. Sound familiar?
The company itself suggests owners may see pets become less food‑motivated, begging less, and scavenging less due to suppressed appetite. That may sound convenient, but it also risks distancing us from the responsibility to understand why our pets overeat, how we feed them, and how much we encourage them to move and play.
The same challenge already exists in humans. GLP‑1 drugs have been transformative and even lifesaving for many people living with obesity and diabetes, and those who medically need them should absolutely have access.
However, we keep seeing them used by people who want a quick cosmetic fix. It is not new for me to say that this takes a resource away from those with a genuine medical need, and that healthy lifestyle changes will be ignored in favor of a prescription.
Loving Our Pets Means Doing The Hard Work
Loving pets enough to keep them with us longer can look unglamorous: measuring food portions; setting boundaries with well‑meaning helpers, family, or ourselves who overfeed; playing with bored indoor cats so they actually move; and accepting that “chubby” is not cute when it comes with aching joints, rising blood sugars, and other health issues. These efforts are less flashy than a monthly implant, but they are powerful medicine in their own right.
If future research shows that GLP‑1 implants are safe and truly beneficial, they may become one more tool in the veterinarian’s toolbox for specific, high‑risk animals. However, this should not become a replacement for loving care, and not a pet version of the weight‑loss trends already sweeping through human culture.
For both people and pets, my thoughts are the same: those who medically need these drugs should have access to them. Those chasing a quick fix deserve a deeper, kinder conversation about health, not just a smaller number on the scale.
